Is Surrozen, Inc. (NASDAQ:SRZN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Surrozen, Inc. at current levels.
Wnt-pathway platform with a Boehringer-validated retinal program and option value the $272M cap doesn't reflect, if cash runway holds.
Where SRZN is headed
By late 2027, Surrozen looks less like a speculative Wnt-pathway story and more like a retinal disease platform with two shots on goal and a partnered third. SZN-413, the Fzd4 bi-specific licensed to Boehringer Ingelheim, should be in human studies, generating the first clinical readouts that prove (or disprove) whether Wnt agonism can do for the retina what anti-VEGF did fifteen years ago. SZN-814, the combined Fzd4 agonist plus VEGF antagonist, is the more interesting asset commercially. If preclinical translates, it offers something Regeneron's Eylea and Roche's Vabysmo cannot: actual vascular repair rather than just suppression of leaky vessels. The DME and wet AMD market is roughly $12 billion annually and growing as the diabetic population swells. A drug that reduces injection burden from every 4-8 weeks to every 12-16 weeks, while also addressing the underlying vascular dysfunction, takes meaningful share.
Read the full Compass Direction on SRZN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $26.37).
See the full SRZN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Surrozen, Inc. (NASDAQ:SRZN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Surrozen, Inc. at current levels. Wnt-pathway platform with a Boehringer-validated retinal program and option value the $272M cap doesn't reflect, if cash runway holds.
What is SRZN's Compass Score?
Surrozen, Inc. scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for SRZN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the SRZN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.